glp-1 agonist oral In the phase 3 ACHIEVE-1 trial, published in June 2025, the small-molecule receptor orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Danuglipron: An Oral GLP-1R Agonist
Pay in 4 interest-free payments of $5.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28


























